Dialysis is a lifesaving treatment. However, dialysis also exerts metabolic, inflammatory and other adverse effects on different organs, such as the cardiovascular system.
In case of PD, the time span in which dialysis may be performed is limited by fibrotic changes in the peritoneal tissue. It is therefore anticipated that by ameliorating these effects not only the duration of PD can be prolonged but overall, the inflammatory burden of disease on the patient can be reduced. Therefore, it seems that a lot may be achieved, by “softening” dialysis treatment.